Attila Fejer – General Manager, Eli Lilly Romania
Attila Fejer general manager of Eli Lilly in Romania gives his insights on the “deadly cocktail” of challenging policies that govern the pharmaceutical industry in the country. He shares the…
Address: Bucharest Business Park (BBP), Str. Menuetului nr. 12, corp D, Et.2, sector 1, cod 013681, Bucuresti, Romania
Tel: 021.402.30.00
Web: http://www.lilly.com/Pages/home.aspx
Eli Lilly Worldwide
• Headquarters located at Indianapolis, Indiana, U.S.A.
• Approximately 40 thousand employees worldwide
• Approximately 8 thousand employees engaged in research and development
• Clinical research conducted in more than 50 countries
• Research and development facilities located in 8 countries
• Manufacturing plants located in 13 countries
• Products marketed in 143 countries
• Net Sales of US $ 21.8 billions for 2009
• R&D expenditure: approx 20% of Sales
Eli Lilly began operations in Romania in the 1990s.
Worldwide, Lilly´s medicines are currently treating schizophrenia, diabetes, bipolar disorder, stress urinary incontinence, erectile dysfunction, depression, cancer, heart disease, pain, infections and gastric disorders and bringing relief to millions of people.
Attila Fejer general manager of Eli Lilly in Romania gives his insights on the “deadly cocktail” of challenging policies that govern the pharmaceutical industry in the country. He shares the…
You have just arrived as general manager in January 2011. Coming to a new market obviously means a new context, different challenges and so on. Can you first elaborate on…
Mirela Iordan country manager of Pfizer Romania reveals some of her milestones, including integrating new acquisitions and setting up the first financial centre in Europe for Pfizer. She shares her…
With the 2019 acquisition of Celgene – one of the largest pharma acquisition in history – two of the sector’s most innovative oncology companies have joined forces to lead the…
According to a 2015 United Nations International Migration Report, since Romania joined the European Union in 2007, around 3.4 million Romanians have left the country in search of a better…
While the dismal regulatory environment in Romania has negatively affected the innovators with the uncertain and lengthy regulatory approval timelines as well as the dreaded ‘clawback tax’ doubling over the…
Stana Moisescu of Teva Pharmaceuticals Romania shares her insights on how to overcome unpredictability and inconsistency at the government level in Romania and why there needs to be a change…
Dan Minoiu, partner at Romanian law firm Mușat & Asociații, shares his insights into the main trends shaping the healthcare environment in Romania from a regulatory and legal perspective, the…
Despite the challenging characteristics of the Romanian market, with a large population of nearly 20 million people and significant unmet medical needs, the country will undoubtedly continue to be strategic…
Sévan Kaloustian shares his first impressions of the Romanian healthcare ecosystem and pharmaceutical market as newly appointed managing director of Janssen Pharmaceutical Companies of Johnson & Johnson Romania. Kaloustian outlines…
Arina Gholmieh introduces the Romanian affiliate of Egis, a leading pharma manufacturer in the Central and Eastern Europe (CEE) region. Gholmieh highlights the difficulties that pharma companies, and especially generic…
Quite unfortunately, Romania has some of the highest infant mortality and maternal mortality rates in Europe, and even more worrying, the downward trend seems to be continuing, most notably with…
Appointed in August 2019 to head up Bayer Romania and Moldova’s Pharmaceuticals division, 15-year Bayer veteran Jorge Levinson may be new to the market but certainly not new to the…
Rostislav Hartman, general manager of the Czech Republic for Zimmer Biomet and who also looks after numerous countries in a dynamic region in Eastern Europe, introduces Zimmer Biomet’s historical presence…
See our Cookie Privacy Policy Here